Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 29, 2013

View Archived Issues

A prognostic peptide-based signature for end-stage renal disease in fetal urinary output

Medimmune to acquire Amplimmune

AiCuris presents a novel class of antibacterial compound with potent activity

An oral multikinase inhibitor shows potent antiangiogenic activity in vivo

Carolus and TAP seek to validate RANTES:Pf-4 as CT-2009 target

Acucela's SEATTLE study reaches half way enrollment

TRPM8 blockade as a potential new treatment strategy for urinary bladder disorders

Licensing and codevelopment agreement for NovaBiotics' first-in-class antifungal peptide

Lee's Pharmaceutical submits CTA to expand the APEX study to China

Orexo updates on OX-51 phase II dose-finding study

Arena Pharmaceuticals completes phase Ib APD-811 trial

FDA accepts for review dabigatran supplemental NDA

U.K.'s NICE does not recommend everolimus use by NHS

Cepheid's Xpert MTB/RIF test categorized by FDA

The University of Virgina presents new sphingosine kinase inhibitors

Novel EGFR inhibitors disclosed by Taiho Pharmaceutical

Scientists at Innate Pharma divulge new MAbs for cancer

Sunovion Pharmaceuticals discloses new antipsychotic agents

FDA extends PDUFA goal date for Xiaflex

Teva decides not to license RX-3117 from Rexahn

Japanese launch for Bonviva injection

Phase II trial planned for CF-102 in hepatocellular carcinoma

Daiichi Sankyo files marketing application for Ranmark in Japan

Grifols and Aradigm close worldwide licensing agreement for inhaled formulations of ciprofloxacin

Europe Commission approves Eylea for visual impairment complications following CRVO

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...